Skip to main content

COVID 19 Updates from RheumNow

Fighting Hydroxychloroquine Misinformation

JAMA Internal Medicine has posted an Editor's note on the use of hydroxychloroquine for COVID-19; noting the sequence of dysfunction since the president promoted its use on March 21, 2020, when he said “What do you have to lose? I’ll say it again: What do you have to lose? Take it.”.

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Colchicine Benefits COVID-19 Patients

A proof-of-concept study published in Annals of Rheumatic Disease suggests that colchicine significantly improves COVID-19 outcomes.

ACR Advice on Reopening Strategies

The American College of Rheumatology (ACR) has issued a guidance document for rheumatologists and rheumatology health professionals to consider as practices, business and patient care begins to reopen in this next phase of the COVID-19 pandemic.

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Low Risk of COVID in Biologic Treated Rheum Patients

In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population. 

Rapid Loss of SARS-CoV-2 Antibodies in Mild Disease

According to a small, observational study out of UCLA published as correspondence in the NEJM on July 21, 2020, those with mild COVID-19 symptoms showed an approximate antibody half-life of 73 days.

Higher Rates of SARS-CoV-2 Seropositivity in the USA

The number of reporting cases of COVID-19 infection tends to underestimate the true prevalence of infection as only the more severe cases (e.g.,acute respiratory syndrome) get tested or go to the hospital.

Steroids and Tocilizumab in Cytokine Storm Syndrome

A recent study from the Netherlands has shown that patients with severe COVID-19-associated cytokine storm syndrome (CSS)  with high dose steroids and tocilizumab had a faster recovery, less need for invasive mechanical ventilation and fewer deaths when compared to CSS patients receiving supporti

RECOVERY Trial: Dexamethasone in COVID-19

Inflammatory events following infection with SARS-CoV-2 can often worsen the morbid or mortal outcomes with COVID, yet it has been unclear if glucocorticoids may modulate inflammation-mediated damage and lung injury.  The RECOVERY trial reports that dexamethasone (DEX) use lowered 28-day mortalit

Characteristics Underlying Mortal COVID-19 Outcomes

From January 1, 2020–May 18, 2020, approximately 1.3 million cases of coronavirus disease 2019 (COVID-19) and 83,000 COVID-19–associated deaths were reported in the United States.

RheumNow Podcast – LTF – Listen to Fauci (7.17.20)

Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow.

Social

A randomized controlled trial testing dexamethasone for Covid-19 (the RECOVERY trial) showed that, compared with usual care, this corticosteroid drug reduced 28-day mortality in hospitalized patients. #COVID19 #SARSCoV2
3 weeks ago
#Texas we REALLY need to #WearAMaskSaveALife ... 6 patients of mine have tested positive for #COVID19 in the last week. #MedTwitter @rheum_covid @COVID19Tracking

Mohammad A. Ursani MD, RhMSUS DrMAUrsani( View Tweet)

3 weeks ago
RheumNow Podcast is Up! Listen to Fauci! Watch it here>> https://t.co/dHq3fP85Ip or Listen to the Podcast>> https://t.co/LdHO7fKUCp

Dr. John Cush RheumNow( View Tweet)

3 weeks 1 day ago
Regeneron/Sanofi have reported their US phase 3 trial of Kevzara (sarilumab) 400 mg given to 194 critically ill COVID-19 patients, requiring mechanical ventilation, did not meet its primary and key secondary endpoints when added to supportive care. https://t.co/UPfGJKWEM9

Dr. John Cush RheumNow( View Tweet)

3 weeks 2 days ago
The preliminary #ACR20 schedule is here! Along with all your favorite plenary and networking sessions, the program will feature #Rheumatologist Dr. Anthony Fauci giving us a live update on #COVID19. @ACRheum #ACRConvergence - Where Rheumatology Meets https://t.co/IWbiVw9PSP

Victoria Shanmugam VickiShanmugam( View Tweet)

3 weeks 3 days ago
NY Times Ranks COVID Rx Tracker: 1) Strong Evidence - Remdesivir, dexamethasone, Ventilation, Proning, anticoagulants; 2) Promising: convalescent plasma, Cytosorb, dialysis; 3) Mixed: IFN, Cytokine inhibitors, Stem Cells; 4) HCQ -not promising https://t.co/sbotsdYcg8

Dr. John Cush RheumNow( View Tweet)

3 weeks 3 days ago
Italian report of 2 cases (1 w/ stable RA;1 without prior arthritis) who developed polyarthritis after hospitalization for COVID pneumonia. Synovial Bx showed synovial proliferation - 1 w/ crystals and both w/ CD3+ and CD138+ cells https://t.co/ZRRrWIjZXg

Dr. John Cush RheumNow( View Tweet)

3 weeks 3 days ago
JAMA Internal Medicine reports that the number of hydroxychloroquine prescriptions increased from 367,346 to 683,999 (86.2%) from February to March 2020, and chloroquine prescriptions increased 158.6%, rising from 2,346 to 6,066 prescriptions. https://t.co/3MKsu5mOpx

Dr. John Cush RheumNow( View Tweet)

3 weeks 3 days ago
×